Baxter’s $338M grab for Prism reflects low-risk acquisition spectrum
This article was originally published in Scrip
Executive Summary
In what might prove to be just one in a spectrum of similar deals, Baxter has definitively agreed to buy in a $338 million deal privately held Prism Pharmaceuticals, a US firm whose major asset is Nexterone, an FDA-approved novel formulation of the antiarrhythmic agent amiodarone.